Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma
ChiCTR2400094398Phase 2Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in thymic carcinoma (TC), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Tumor objective response rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2400094398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094398.